Fantastic news!
Can we expect a de novo update before the end of the year? Time will tell. Data is very convincing in this early study. Pleased they mentioned difficulty with positioning at one point, all of which will be improved with gen2.
Congratulations to Team EMV and GLTAH.
Ann: Clinical Trial Data Drives Confidence for Expanded Studies, page-3
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.03 |
Change
0.080(4.10%) |
Mkt cap ! $173.4M | |||
| Open | High | Low | Value | Volume |
| $1.98 | $2.03 | $1.97 | $65.64K | 33.17K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15452 | $1.98 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 3999 | 1 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| EMV (ASX) Chart |